Search Results
Your search for ,USE matches 11256 pages
Showing 5551 - 5600Maintenance Therapy for Metastatic Colorectal Cancer: Benefit Seen With Panitumumab Combination
Although the optimal approach to maintenance is not definitive in patients with metastatic colorectal cancer who have undergone chemotherapy-based induction with anti–endothelial growth factor receptor (EGFR) agents, the phase II VALENTINO trial showed that anti-EGFR maintenance therapy with...
Pembrolizumab for Advanced Cervical Cancer Progressing During or After Chemotherapy
In June 2018, pembrolizumab (Keytruda) was approved for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express programmed cell death ligand 1 (PD-L1; combined positive score [CPS] ≥ 1), as determined by a U.S....
Durable Responses With Moxetumomab Pasudotox in Pretreated Hairy Cell Leukemia
Moxetumomab pasudotox produced deep and durable responses in a heavily pretreated population of patients with hairy cell leukemia, with the ability to eradicate minimal residual disease. The drug showed a favorable safety profile with less bone marrow suppression than with purine nucleoside analog...
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On June 13, 2018, pembrolizumab (Keytruda) was granted...
Update on Clinical Trials of Novel Therapies
Long-term follow-up data on axicabtagene ciloleucel (Yescarta) in lymphoma, potential partners for nivolumab (Opdivo) in solid tumors, and a targeted agent for RET-altered cancers were featured during the developmental therapeutics program at the 2018 ASCO Annual Meeting. At the Best of ASCO...
An Invitation to Be Quiet No Longer
My male colleagues sometimes broach the topic of #MeToo or sexual harassment in medicine by saying how uncomfortable it makes them. Ah, yes. How uncomfortable the sexual harassment I have faced for years makes you. I casually bring up microaggressions—subtle verbal or nonverbal slights against...
Treatment of Triple-Negative Breast Cancer With BRCA1/2 Mutations: More to Learn From Ongoing Trials
The treatment of triple-negative breast cancer remains a clinical challenge with no single validated target, though numerous pathways are druggable and are being investigated. In the subset of BRCA-mutated triple-negative breast cancer, the approval of the first poly (ADP-ribose) polymerase (PARP)...
Cabozantinib in Second-Line Treatment of Advanced Hepatocellular Carcinoma
Compared with placebo, cabozantinib (Cabometyx) significantly improved overall survival and progression-free survival in patients with advanced hepatocellular carcinoma who were previously treated with sorafenib (Nexavar), with no new safety signals, according to data from the phase III CELESTIAL ...
Childhood Nonlymphoid Leukemia Risk With Maternal Use of Hormonal Contraception
In a population-based cohort study reported in The Lancet Oncology, Hargreave et al found that recent maternal use of hormonal contraception was associated with increased risk of childhood nonlymphoid leukemia. Study Details The study involved data from a nationwide cohort of...
FDA Takes New Steps to Address Youth E-Cigarette Use
The U.S. Food and Drug Administration (FDA) has announced a series of critical and historic enforcement actions related to the sale and marketing of e-cigarettes to children. In the largest coordinated enforcement effort in the its history, the agency issued more than 1,300 warning...
Neonatal Dysregulated Immune Function and Pediatric B-Cell Precursor ALL
A high incidence of clinically diagnosed infections in the first year of life among children who later developed acute lymphoblastic leukemia (ALL) has led researchers to propose that children with ALL are born with a dysregulated immune function, resulting in a more vigorous reaction to infections ...
Survey Shows Increased Public Awareness of Lung Cancer Over Past Decade
Survey results released by the Lung Cancer Alliance (LCA) show that general awareness about lung cancer has improved significantly over the past decade, with 94% of the public reporting familiarity with lung cancer. Despite this change in overall perspective, findings also indicate that lung cancer ...
FDA Approves Moxetumomab Pasudotox-tdfk for the Treatment of Hairy Cell Leukemia
The U.S. Food and Drug Administration (FDA) today approved moxetumomab pasudotox-tdfk (Lumoxiti) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with...
Presurgical CT Imaging of CD117-Positive Kidney Tumors
A research team from Roswell Park Comprehensive Cancer Center has discovered a way to use computed tomography (CT) imaging to assess kidney tumors that test positive for the biomarker CD117 and accurately determine—before surgery—whether the tumor is benign or malignant. Their findings...
Bleomycin-Related Toxicity and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Germ Cell Tumors
In a retrospective single-institution analysis reported in the Journal of Clinical Oncology, Calaway et al found that the addition of bleomycin to etoposide/cisplatin did not appear to increase risk of pulmonary or postoperative morbidity after postchemotherapy retroperitoneal lymph node dissection ...
Lasker Foundation Announces 2018 Lasker Awards for Basic and Clinical Medical Research and Special Achievement
The Albert and Mary Lasker Foundation today announced the winners of its 2018 Lasker Awards: C. David Allis, PhD, of Rockefeller University and Michael Grunstein, PhD, of the University of California, Los Angeles, will receive the Albert Lasker Basic Medical Research...
Applying for a Conquer Cancer Research Grant: Tips From Past YIA and CDA Recipients
Research grants are vital to the success of academic research and researchers apply for these grants at all stages of their career. This makes writing stand-out grant applications an incredibly valuable skill for clinical investigators—and an intimidating task for first-time grant applicants....
Georgetown Launches Open Access Brain Cancer Biomedical Database
THE GEORGETOWN Lombardi Comprehensive Cancer Center has developed and released a cache of brain cancer biomedical data and made them freely available to researchers worldwide. The database, referred to as REMBRANDT (Repository for Molecular Brain Neoplasia Data), contains information on 671 adult...
Expanding the Use of Provider Orders for Life-Sustaining Treatment for Patients With Advanced Cancer
Patients with advanced cancer often get more aggressive treatment than they want because too few oncologists elicit their end-of-life treatment preferences.1,2 In response to this problem, leading associations, including ASCO3,4 and the Institute of Medicine,5 have called for more advance care...
Brian C. Capell, MD, PhD, Receives Award for Skin Cancer Research
BRIAN C. CAPELL, MD, PhD, Assistant Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania, has received a Damon Runyon Clinical Investigator Award. He plans to use the $450,000 research grant to study epigenetic targets in the skin to develop more effective...
Challenges of Managing Older Patients With Diffuse Large B-Cell Lymphoma
As the population continues to age, the interplay between aging and cancer increasingly shows cancer to be a disease of older people. By the year 2030, there will be an increased incidence of non-Hodgkin lymphoma (NHL) in older individuals.1 The median age of patients diagnosed with diffuse large...
Chemotherapy for Acute Myeloid Leukemia: Where Should It Be Given?
USING THE National Cancer Database, Bhatt et al1 recently reported that of the 61,775 adults with acute myeloid leukemia (AML), those who received chemotherapy from 2003 to 2011 lived longer than those who, in those same years, did not; the study is reviewed in this issue of The ASCO Post....
Suboptimal Use of Initial Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia
IN A STUDY of National Cancer Database data reported in Blood Advances, Vijaya Raj Bhatt, MD, of the University of Nebraska Medical Center, and colleagues found that 25% of patients with newly diagnosed acute myeloid leukemia (AML) did not receive initial chemotherapy, despite evidence that...
Expert Point of View: Ian Olver, MD, PhD
COMMENTING ON the importance of this topic at a press conference during the 2018 Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) Annual Meeting, Ian Olver, MD, PhD, Immediate Past President of MASCC and Director of the University of...
Recent Drug Approvals and Revisions in Prescribing Information
THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) issued the following approvals and prescribing information revisions in August 2018. Lenvatinib Approved for Unresectable Hepatocellular Carcinoma THE FDA approved lenvatinib (Lenvima) for the first-line treatment of patients with unresectable...
Adding Nimotuzumab to Chemoradiation Improved Survival in Locally Advanced Head and Neck Cancer
IN PATIENTS with locally advanced squamous cell carcinoma of the head and neck, nimotuzumab—a humanized monoclonal antibody against the epidermal growth factor receptor—in combination with cisplatin and radiotherapy was superior to cisplatin and radiotherapy alone in improving progression-free...
FDA Approves First Nonchemotherapy Combination Regimen for Patients With Waldenström’s Macroglobulinemia
ON AUGUST 27, 2018, the U.S. Food and Drug Administration (FDA) approved the combination of ibrutinib (Imbruvica) and rituximab (Rituxan) for patients with Waldenström’s macroglobulinemia. The recent approval expands the label for ibrutinib in Waldenström’s macroglobulinemia beyond its current...
Relapsed or Refractory Hodgkin Lymphoma: Optimizing Salvage Therapy
As novel therapies come on board for treating relapsed or refractory Hodgkin lymphoma, the field is advancing toward more personalized therapy. The goal, even in the advanced-disease setting, is to increase the chances of complete response and negative positron-emission tomography (PET), while...
Proteomics May Be Used to Predict Treatment Outcomes in Triple-Negative Breast Cancer
In triple-negative breast cancer, researchers have so far been unable to identify markers that can classify patients by prognosis or probability of responding to different treatments. In a study published by Zagorac et al in Nature Communications, researchers from the Spanish National Cancer...
Immune Checkpoint Inhibitors in Patients With HIV-Associated Kaposi Sarcoma
Widespread use of antiretroviral therapy in the treatment of patients infected with human immunodeficiency virus (HIV) has led to a decline in the incidence of HIV-related Kaposi sarcoma, an incurable malignancy associated with HIV. Nevertheless, about 15% of these patients will go on to...
Treating Nonmetastatic Castration-Resistant Prostate Cancer: Implications of the PROSPER Trial
A MAN in his early 70s sits in our office. His general health is good, and he is feeling well. Yet he is deeply worried. Four years ago, when his prostate-specific antigen (PSA) level rapidly increased after radical prostatectomy and subsequent radiation therapy, he was started on...
Overall Survival Improved With Encorafenib/Binimetinib Combination in BRAF-Mutant Melanoma
IN PATIENTS with advanced BRAF V600–mutant melanoma, combining the BRAF inhibitor encorafenib (Braftovi) with the MEK inhibitor binimetinib (Mektovi) improved overall survival compared to vemurafenib (Zelboraf) or encorafenib as monotherapy, with a favorable toxicity profile, according to updated...
NCCN and CAOH Develop Guidelines to Improve Cancer Care in the Caribbean
The National Comprehensive Cancer Network® (NCCN®) is embarking on a new collaboration with the Caribbean Association for Oncology & Hematology (CAOH) to develop a library of NCCN Harmonized Guidelines™ for the Caribbean. The archipelago that extends from the Bahamas in the north to Trinidad...
Protein-Metabolite Panel for Detection of Early-Stage Pancreatic Cancer
In a study reported in the Journal of the National Cancer Institute, Fahrmann et al developed and validated a plasma-derived metabolite panel that distinguished early-stage pancreatic ductal adenocarcinoma (PDAC) with high accuracy. Accuracy was further improved with the addition of a previously...
Coriolus versicolor
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, present information on the potential...
Ribociclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On July 18, 2018, the indication for ribociclib (Kisqali) ...
Love in the Time of Cancer
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Ipilimumab in Combination With Nivolumab for MSI-H or dMMR Metastatic Colorectal Cancer
On July 10, 2018, ipilimumab (Yervoy) was granted accelerated approval for use in combination with nivolumab (Opdivo) for the treatment of patients at least 12 years of age with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer progressing...
Medical Groups Release Letter on Proposed Changes to Medicare Physician Payment Rule
The American Medical Association and about 150 medical groups sent the following letter to Seema Verma, Administrator of the Centers for Medicare and Medicaid Services (CMS), regarding the administration’s proposals included in the 2019 Medicare physician payment rule. The full text of...
FDA Approves cobas EGFR Mutation Test v2 as Companion Diagnostic With Gefitinib in First-Line Treatment of NSCLC
The U.S. Food and Drug Administration (FDA) recently approved the cobas EGFR Mutation Test v2 as a companion diagnostic test with gefitinib (Iressa) for the first-line treatment of patients with non–small cell lung cancer (NSCLC). A companion diagnostic test provides information that is...
ICER Report on Clinical Benefits and Value of Different Antiandrogen Therapies for Men With Nonmetastatic Castration-Resistant Prostate Cancer
The Institute for Clinical and Economic Review (ICER) has released an evidence report assessing the comparative clinical effectiveness and value of antiandrogen therapies for the treatment of nonmetastatic castration-resistant prostate cancer. The report focuses on three antiandrogen...
Baseline Steroids and Efficacy of PD-1/PD-L1 Inhibitors in NSCLC
In a study reported in the Journal of Clinical Oncology, Arbour et al found that baseline treatment with corticosteroids was associated with poorer efficacy of programmed cell death protein 1 (PD-1) or programmed death cell ligand 1 (PD-L1) inhibitors in patients with non–small cell lung...
FDA Approves Ibrutinib Plus Rituximab for Waldenström’s Macroglobulinemia
The U.S. Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica) plus rituximab (Rituxan) for the treatment of adult patients with Waldenström's macroglobulinemia (WM). With this approval, the ibrutinib prescribing information now includes combination use with rituximab,...
New Software Aims to Predict Patients’ Resistance to Cancer Treatment
New computer software may be used to predict how cancers may respond to a new drug—before it has ever been given to patients. Researchers hope that this new tool could transform the discovery of cancer drugs by predicting how tumors become resistant to treatment before it first becomes...
Dutch Quality-of-Life Study With One- vs Two-Stage Breast Reconstruction in Skin-Sparing Mastectomy
In a Dutch study reported in The Lancet Oncology, Negenborn et al found no differences in quality of life (QOL) between women receiving one-stage implant-based breast reconstruction (IBBR) with an acellular dermal matrix (ADM) vs standard two-stage IBBR. A previously reported safety analysis from...
Most Oncologists Have Discussed Medical Marijuana With Patients, Survey Finds
DATA FROM a new survey show that as many as 80% of oncologists have discussed medical marijuana use with their patients. According to the authors, this is the first nationally representative survey to examine oncologists’ practices and beliefs on the subject since the implementation of state...
Fox Chase Cancer Center Welcomes Surgeon Shreyas S. Joshi, MD
FOX CHASE CANCER CENTER recently announced the hiring of Shreyas S. Joshi, MD, an attending surgeon who recently completed a 2-year urologic oncology fellowship at the institution. Dr. Joshi is board-eligible in urology and earned his medical degree from Indiana University School of Medicine. He ...
I Am Too Young for Breast Cancer
Two years ago, when I began having pain and bloody discharge in my left breast, I thought it was the return of a solitary intraductal papilloma I had had in that breast when I was a college student 6 years earlier, so the symptoms didn’t initially alarm me. It wasn’t until I noticed that the mass...
Blinatumomab in Adult and Pediatric Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
EARLY IN 2018, blinatumomab (Blincyto) was granted accelerated approval for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease ≥ 0.1%.1,2 Supporting Efficacy Data APPROVAL WAS...
Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia
ON JULY 20, 2018, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as detected by an FDA-approved test.1,2 The FDA...
